Serena TE
Diagnostics (Basel, Switzerland). Date of publication 2020 Nov 26;volume 10(12):.
1. Diagnostics (Basel). 2020 Nov 26;10(12). pii: E1010. doi:
10.3390/diagnostics10121010.
Incorporating Point-of-Care Bacterial Fluorescence into a Wound Clinic
Antimicrobial Stewardship Program.
Serena TE(1).
Author information:
(1)SerenaGroup Research Foundation, Cambridge, MA 02140, USA.
BACKGROUND: In 2014 the World Health Organization (WHO) warned of an emerging
world-wide crisis of antibiotic-resistant microorganisms. In response, government
and professional organizations recommended that health care systems adopt
antimicrobial stewardship programs (ASPs). In the United States, the Centers for
Medicare Services (CMS) mandated antimicrobial stewardship in the hospital
inpatient setting. Effective 1 January 2020, the Joint Commission required
ambulatory centers that prescribe antibiotics, such as wound centers, to
institute an ASP. Chronic wounds often remain open for months, during which time
patients may receive multiple courses of antibiotics and numerous antimicrobial
topical treatments. The wound clinician plays an integral role in reducing
antimicrobial resistance in the outpatient setting: antibiotics prescribed for
skin and soft tissue infections are among the most common in an outpatient
setting. One of the most challenging aspects of antimicrobial stewardship in
treating chronic wounds is the inaccuracy of bacterial and infection diagnosis.
METHODS: Joint Commission lists five elements of performance (EP): (1)
identifying an antimicrobial stewardship leader; (2) establishing an annual
antimicrobial stewardship goal; (3) implementing evidence-based practice
guidelines related to the antimicrobial stewardship goal; (4) providing clinical
staff with educational resources related to the antimicrobial stewardship goal;
and (5) collecting, analyzing, and reporting data related to the antimicrobial
stewardship goal. This article focuses on choosing and implementing an
evidence-based ASP goal for 2020.
DISCUSSION: Clinical trials have demonstrated the ability of fluorescence imaging
(MLiX) to detect clinically significant levels of bacteria in chronic wounds.
Combined with clinical examination of signs and symptoms of infection, the MLiX
procedure improves the clinician's ability to diagnose infection and can guide
antimicrobial use. In order to satisfy the elements of performance, the MLiX
procedure was incorporated into the annual ASP goal for several wound care
centers. Clinicians were educated on the fluorescence imaging device and
guidelines were instituted. Collection of antimicrobial utilization data is
underway.
DOI: 10.3390/diagnostics10121010
PMCID: PMC7760918
PMID: 33255867
Appears in following Topics: